drugset

drugset / Trial / NCT01270906

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

NCT01270906 ↗

Phase 1 Terminated 35 enrolled Novartis Pharmaceuticals Chiron Corporation · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase I dose finding study in solid tumors.

Timeline

Start: 2003-12
Primary completion: 2006-10
Completion: —

Publications

Wang X, Kay A, Anak O, Angevin E, Escudier B, Zhou W, Feng Y, Dugan M, Schran H. Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib. J Clin Pharmacol. 2013 Jan;53(1):14-20. doi: 10.1177/0091270011433330. Epub 2013 Jan 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CHIR-258	Unknown	—	Oral

Indications